BridgeBio Pharma Announces Pricing Of 5,000,000-Share Secondary Offering By Selling Stockholder KKR Genetic Disorder; Company Receives No Proceeds
Share
Why It Matters
A big investor named KKR is selling 5 million shares of BridgeBio stock, but the company itself doesn't get any money from this sale. When a large owner sells shares, it can change how many people own the company, so watch if the stock price moves or if other investors seem worried.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.